Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • MapLight shares sink on mixed phase 2 schizophrenia readout

MapLight shares sink on mixed phase 2 schizophrenia readout

July 27, 2026Posted inBiotechnology

MapLight Therapeutics’ stock plummeted more than 60% this morning after the neuro outfit dropped mixed results for a phase 2 trial of its experimental schizophrenia treatment.

Post navigation

Previous Post
sericin-directs-silk-fibroin-assembly-into-ordered-nanofibrils,-study-finds Sericin directs silk fibroin assembly into ordered nanofibrils, study finds
Next Post
Apnimed aspires for up to $160M IPO as sleep apnea pill launch nears

Recent Posts

  • Multidisciplinary Neurohemodynamics Team Improves Echocardiography-Guided Care for Neonatal AVMs
  • Dopamine-Linked Brain Network Reconfiguration Dynamics Altered in Parkinson’s Disease
  • Programmable DNA tetrahedra enable selective, efficient capture of cells and proteins
  • APREAL Fall-Prevention Program Improves Safety for Hospitalized Elderly Patients
  • Atmospheric Water Harvesting Enables Humidity Control in Medical Devices Worldwide

Archives

  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • March 2024
  • January 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top